Skip to contentT
TuHURA Biosciences, Inc.
T
HURATuHURA Biosciences, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2024 Net Income-$6.76M-$6.76MderivedN/M vs Q4 2024 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TuHURA Biosciences, Inc. · CIK 1498382 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,556,022N/M Free Cash Flowderived-$5,583,872N/M ended Dec 31, 2025 · filed Mar 31, 2026 · 90 d after period end